EA202190619A1 - Противовирусные соединения - Google Patents

Противовирусные соединения

Info

Publication number
EA202190619A1
EA202190619A1 EA202190619A EA202190619A EA202190619A1 EA 202190619 A1 EA202190619 A1 EA 202190619A1 EA 202190619 A EA202190619 A EA 202190619A EA 202190619 A EA202190619 A EA 202190619A EA 202190619 A1 EA202190619 A1 EA 202190619A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compounds
antiviral compounds
methods
antiviral
preparing
Prior art date
Application number
EA202190619A
Other languages
English (en)
Inventor
Элизабет М. Бэйкон
Джероми Дж. Коттелл
Эшли Энн Катана
Дэррил Като
Эван С. Крыговский
Джон О. Линк
Джеймс Тэйлор
Чинх Вьет Трен
Тереса Алехандра Трехо Мартин
Чжэн-Юй Ян
Шейла Зипфел
Original Assignee
Джилид Фармассет Ллс
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47324426&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA202190619(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Джилид Фармассет Ллс filed Critical Джилид Фармассет Ллс
Publication of EA202190619A1 publication Critical patent/EA202190619A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

Настоящее изобретение относится к противовирусным соединениям, композициям, содержащим указанные соединения, и терапевтическим способам, которые включают введение указанных соединений, а также к способам и промежуточным соединениям, подходящим для получения указанных соединений.
EA202190619A 2011-11-16 2012-11-16 Противовирусные соединения EA202190619A1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161560654P 2011-11-16 2011-11-16

Publications (1)

Publication Number Publication Date
EA202190619A1 true EA202190619A1 (ru) 2021-09-30

Family

ID=47324426

Family Applications (4)

Application Number Title Priority Date Filing Date
EA201890333A EA037883B1 (ru) 2011-11-16 2012-11-16 Противовирусные соединения
EA202190619A EA202190619A1 (ru) 2011-11-16 2012-11-16 Противовирусные соединения
EA201591244A EA030941B1 (ru) 2011-11-16 2012-11-16 Противовирусные соединения
EA201390576A EA023644B1 (ru) 2011-11-16 2012-11-16 Противовирусные соединения

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA201890333A EA037883B1 (ru) 2011-11-16 2012-11-16 Противовирусные соединения

Family Applications After (2)

Application Number Title Priority Date Filing Date
EA201591244A EA030941B1 (ru) 2011-11-16 2012-11-16 Противовирусные соединения
EA201390576A EA023644B1 (ru) 2011-11-16 2012-11-16 Противовирусные соединения

Country Status (37)

Country Link
US (14) US20130164260A1 (ru)
EP (4) EP2907816B1 (ru)
JP (5) JP6082749B2 (ru)
KR (5) KR20190121406A (ru)
CN (2) CN103328480B (ru)
AP (1) AP2013006877A0 (ru)
AU (1) AU2012318253B8 (ru)
BR (1) BR112013012091A2 (ru)
CA (2) CA2815082C (ru)
CL (1) CL2013001428A1 (ru)
CO (1) CO6791562A2 (ru)
CR (1) CR20130231A (ru)
CY (2) CY1116987T1 (ru)
DK (2) DK2635588T3 (ru)
EA (4) EA037883B1 (ru)
EC (2) ECSP13012790A (ru)
ES (3) ES2843023T3 (ru)
HK (1) HK1188989A1 (ru)
HR (2) HRP20150725T1 (ru)
HU (2) HUE027733T2 (ru)
IL (5) IL226345A (ru)
LT (1) LT2907816T (ru)
MA (1) MA34727B1 (ru)
MD (2) MD4403C1 (ru)
ME (1) ME02196B (ru)
MX (3) MX346729B (ru)
MY (1) MY173045A (ru)
PE (2) PE20171444A1 (ru)
PH (1) PH12015502839B1 (ru)
PL (3) PL2907816T3 (ru)
PT (3) PT2907816T (ru)
RS (2) RS54207B1 (ru)
SG (1) SG10201700947UA (ru)
SI (3) SI3431477T1 (ru)
SM (1) SMT201500197B (ru)
UA (2) UA119437C2 (ru)
WO (1) WO2013075029A1 (ru)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2604620T (lt) 2003-05-30 2016-09-12 Gilead Pharmasset Llc Modifikuoti fluorintų nukleozidų analogai
MX360800B (es) 2009-05-13 2018-11-16 Gilead Pharmasset Llc Star Compuestos antivirales.
PT2640719T (pt) 2010-11-17 2017-07-25 Gilead Pharmasset Llc Compostos antivirais
KR20140053166A (ko) 2011-07-09 2014-05-07 선샤인 레이크 파르마 컴퍼니 리미티드 C형 간염 바이러스 억제제로서 스피로 화합물
LT2709613T (lt) 2011-09-16 2018-02-12 Gilead Pharmasset Llc Žmogaus hepatito viruso (hcv) gydymo būdai
UA119437C2 (uk) 2011-11-16 2019-06-25 Гайлід Фармассет Елелсі Противірусні сполуки
US9326973B2 (en) 2012-01-13 2016-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20130309196A1 (en) 2012-05-16 2013-11-21 Gilead Sciences, Inc. Antiviral compounds
PE20151778A1 (es) 2013-01-31 2015-12-16 Gilead Pharmasset Llc Formulacion combinada de dos compuestos antivirales
US10032995B2 (en) 2013-02-07 2018-07-24 Kyulux, Inc. Compound having diazatriphenylene ring structure, and organic electroluminescent device
WO2014185995A1 (en) * 2013-05-16 2014-11-20 Gilead Pharmasset Llc Hepatitis c treatments with sofosbuvir
US20150023913A1 (en) 2013-07-02 2015-01-22 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
ES2680550T3 (es) * 2013-07-09 2018-09-10 Bristol-Myers Squibb Company Combinaciones de inhibidores del virus de la hepatitis C
CN105530933B (zh) 2013-07-17 2018-12-11 百时美施贵宝公司 用于治疗hcv的包含联苯衍生物的组合产品
SI3038601T1 (sl) 2013-08-27 2020-07-31 Gilead Pharmasset Llc Formulacija kombinacije dveh protivirusnih spojin
WO2015030854A1 (en) 2013-08-27 2015-03-05 Gilead Pharmasset Llc Solid dispersion formulation of an antiviral compound
CN104418784B (zh) * 2013-09-04 2019-02-19 浙江九洲药业股份有限公司 一种抗病毒药物中间体的拆分方法
US9562058B2 (en) 2013-12-23 2017-02-07 Gilead Sciences, Inc. Crystalline forms of an antiviral compound
TWI721947B (zh) * 2014-06-11 2021-03-21 美商基利法瑪席特有限責任公司 抗病毒化合物的固態形式
TWI679203B (zh) * 2014-06-11 2019-12-11 美商基利法瑪席特有限責任公司 製備抗病毒化合物之方法
KR20230130175A (ko) 2014-12-26 2023-09-11 에모리 유니버시티 Ｎ4-하이드록시시티딘, 이와 관련된 유도체 및 이의 항 바이러스적 용도
CN105801462A (zh) * 2014-12-29 2016-07-27 重庆博腾制药科技股份有限公司 一种(4S)-N-Boc-4--甲氧基甲基-L-脯氨酸的合成方法
CN104586802B (zh) * 2015-02-02 2018-01-16 长春海悦药业股份有限公司 一种含有索菲布韦的药物组合物
CN106008552B (zh) * 2015-03-01 2020-08-21 南京圣和药业股份有限公司 苯并[e]吡唑并[1,5-c][1,3]噁嗪类化合物及其应用
WO2017023631A1 (en) 2015-08-06 2017-02-09 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2017060820A1 (en) * 2015-10-08 2017-04-13 Mylan Laboratories Limited Process for the preparation of velpatasvir
CN105294713A (zh) * 2015-10-09 2016-02-03 重庆康施恩化工有限公司 Velpatasvir中间体及其制备方法
CN105801553B (zh) * 2016-04-12 2018-06-19 爱斯特（成都）生物制药股份有限公司 一种苯并色烯衍生物的制备方法
CN106916134B (zh) * 2016-04-14 2020-04-17 苏州楚凯药业有限公司 一种10,11-二氢-5H-苯并[d]萘并[2,3-b]吡喃酮衍生物的制备方法
WO2017184670A2 (en) 2016-04-22 2017-10-26 Gilead Sciences, Inc. Methods for treating zika virus infections
WO2017191546A1 (en) * 2016-05-05 2017-11-09 Laurus Labs Private Ltd. Process for the preparation of intermediates useful in the preparation of hepatitis c virus (hcv) inhibitors
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
EP3454862A4 (en) 2016-05-10 2020-02-12 C4 Therapeutics, Inc. SPIROCYCLIC DEGRONIMERS FOR TARGET PROTEIN REDUCTION
WO2017197055A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
SG11201809893WA (en) 2016-05-27 2018-12-28 Gilead Sciences Inc Methods for treating hepatitis b virus infections using ns5a, ns5b or ns3 inhibitors
BR102017011025A2 (pt) 2016-06-02 2017-12-19 Gilead Pharmasset Llc Formulation of combination of three antiviral compounds
WO2018006811A1 (zh) * 2016-07-08 2018-01-11 深圳市塔吉瑞生物医药有限公司 一种取代的咪唑基化合物及其药物组合物
KR101887969B1 (ko) * 2016-08-30 2018-08-13 한국과학기술연구원 항바이러스 활성을 가지는 카르바졸 화합물
CN107674064B (zh) * 2016-11-30 2020-03-27 上海博志研新药物技术有限公司 维帕他韦中间体、制备方法及维帕他韦的制备方法
CN106831737B (zh) * 2017-02-27 2020-03-17 上海众强药业有限公司 维帕他韦及其衍生物的制备
CN107501280A (zh) * 2017-09-05 2017-12-22 安徽华昌高科药业有限公司 一种维帕他韦的合成方法
US10849960B2 (en) 2017-09-08 2020-12-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Synergistic combination of IL-4, interferon gamma, and interferon alpha in treating ovarian cancer
CN107655986B (zh) * 2017-09-08 2020-11-03 安徽一灵药业有限公司 一种维帕他韦有关物质的检测方法
KR102248165B1 (ko) 2017-12-07 2021-05-06 에모리 유니버시티 N4-하이드록시사이티딘 및 유도체 및 이와 관련된 항-바이러스 용도
CN108276421B (zh) * 2018-02-13 2019-08-06 浙江永太药业有限公司 一种维帕他韦的合成方法
BR112021013607A2 (pt) 2019-10-18 2022-06-07 Wockhardt Ltd Compostos bicíclico contendo nitrogênio
CN111018870B (zh) * 2019-11-29 2021-07-23 南京正济医药研究有限公司 一种维帕他韦中间体的制备方法
CN110981879B (zh) * 2019-12-09 2021-03-05 南通常佑药业科技有限公司 一种制备ns5a抑制剂-维帕他韦的方法
CN113072615B (zh) * 2021-03-24 2023-01-10 上海法默生物科技有限公司 一种维帕他韦中间体的制备方法
WO2022246109A1 (en) * 2021-05-21 2022-11-24 Gilead Sciences, Inc. Pentacyclic derivatives as zika virus inhibitors

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816570A (en) 1982-11-30 1989-03-28 The Board Of Regents Of The University Of Texas System Biologically reversible phosphate and phosphonate protective groups
US4968788A (en) 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
JP3347723B2 (ja) 1990-06-13 2002-11-20 グラツィエル，アーノルド 含リンプロドラッグ
DE10399025I2 (de) 1990-09-14 2007-11-08 Acad Of Science Czech Republic Wirkstoffvorläufer von Phosphonaten
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
US5858389A (en) 1996-08-28 1999-01-12 Shaker H. Elsherbini Squalene is an antiviral compound for treating hepatitis C virus carriers
US6841566B2 (en) 2001-07-20 2005-01-11 Boehringer Ingelheim, Ltd. Viral polymerase inhibitors
KR101164070B1 (ko) 2003-05-09 2012-07-12 베링거 인겔하임 인터내셔날 게엠베하 Ｃ형 간염 바이러스 ｎｓ5ｂ 폴리머라제 억제제 결합 포켓
US7157492B2 (en) 2004-02-26 2007-01-02 Wyeth Dibenzo chromene derivatives and their use as ERβ selective ligands
AU2005274700B2 (en) 2004-07-16 2011-11-10 Gilead Sciences, Inc. Antiviral compounds
US8891379B2 (en) 2006-06-02 2014-11-18 Riverbed Technology, Inc. Traffic flow inference based on link loads and gravity measures
US7659270B2 (en) * 2006-08-11 2010-02-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8329159B2 (en) 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7759495B2 (en) * 2006-08-11 2010-07-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TWI442947B (zh) 2006-12-07 2014-07-01 Daiichi Sankyo Co Ltd 安定性經改善之薄膜塗覆製劑
US7741347B2 (en) 2007-05-17 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2009102621A2 (en) * 2008-02-11 2009-08-20 Qualcomm Mems Technologies, Inc. Methods for measurement and characterization of interferometric modulators
EP2250163B1 (en) 2008-02-12 2012-03-28 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US8147818B2 (en) * 2008-02-13 2012-04-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7704992B2 (en) 2008-02-13 2010-04-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2009102325A1 (en) 2008-02-13 2009-08-20 Bristol-Myers Squibb Company Imidazolyl biphenyl imidazoles as hepatitis c virus inhibitors
US20100256184A1 (en) 2008-08-13 2010-10-07 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US8729077B2 (en) * 2008-11-28 2014-05-20 Glaxosmithkline Llc Anti-viral compounds, compositions, and methods of use
BRPI0922364A2 (pt) 2008-12-03 2017-08-29 Presidio Pharmaceuticals Inc Composto, composição farmacêutica e uso de um composto
EP2398474A4 (en) * 2009-02-23 2012-12-05 Presidio Pharmaceuticals Inc HCV NS5A SHEMMER
SG174146A1 (en) 2009-02-27 2011-10-28 Enanta Pharm Inc Hepatitis c virus inhibitors
BRPI1012282A2 (pt) 2009-03-27 2015-09-22 Presidio Pharmaceuticals Inc inibidores de anel fundidos da hepatite c.
WO2010111673A1 (en) 2009-03-27 2010-09-30 Presidio Pharmaceuticals, Inc. Substituted bicyclic hcv inhibitors
JP2012526834A (ja) 2009-05-12 2012-11-01 シェーリング コーポレイション ウイルス疾患治療に有用な縮合型三環式アリール化合物
MX360800B (es) * 2009-05-13 2018-11-16 Gilead Pharmasset Llc Star Compuestos antivirales.
TWI598358B (zh) 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 核苷磷醯胺
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
US8138215B2 (en) 2009-05-29 2012-03-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8344155B2 (en) 2009-09-04 2013-01-01 Glaxosmith Kline Llc Chemical compounds
EP2475256A4 (en) 2009-09-11 2013-06-05 Enanta Pharm Inc HEPATITIS C-VIRUS HEMMER
AU2010324871A1 (en) * 2009-11-25 2012-06-14 Merck Sharp & Dohme Corp. Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases
US8476225B2 (en) 2009-12-04 2013-07-02 Gilead Sciences, Inc. Antiviral compounds
US8377980B2 (en) 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN104530079B (zh) * 2009-12-18 2017-10-20 北京凯因科技股份有限公司 C型肝炎病毒复制的新型抑制剂
US20130156731A1 (en) * 2009-12-22 2013-06-20 Kevin X. Chen Fused tricyclic compounds and methods of use thereof for the treatment of viral diseas
SG183526A1 (en) 2010-03-09 2012-09-27 Merck Sharp & Dohme Fused tricyclic silyl compounds and methods of use thereof for the treatment of viral diseases
US9125904B1 (en) 2010-05-11 2015-09-08 Achillion Pharmaceuticals, Inc. Biphenyl imidazoles and related compounds useful for treating HCV infections
US20110312996A1 (en) 2010-05-17 2011-12-22 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
BR112013004520A2 (pt) 2010-08-26 2016-06-07 Univ Emory inibidores potentes e seletivos do virus da hepatite c
WO2012048421A1 (en) 2010-10-14 2012-04-19 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor compounds
PT2640719T (pt) 2010-11-17 2017-07-25 Gilead Pharmasset Llc Compostos antivirais
WO2012087976A2 (en) 2010-12-21 2012-06-28 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
UA119437C2 (uk) 2011-11-16 2019-06-25 Гайлід Фармассет Елелсі Противірусні сполуки
WO2013101550A1 (en) 2011-12-29 2013-07-04 Abbvie Inc. Solid compositions comprising an hcv inhibitor
US9079887B2 (en) 2012-05-16 2015-07-14 Gilead Sciences, Inc. Antiviral compounds
US20130309196A1 (en) 2012-05-16 2013-11-21 Gilead Sciences, Inc. Antiviral compounds
US9233974B2 (en) 2012-12-21 2016-01-12 Gilead Sciences, Inc. Antiviral compounds
SI3038601T1 (sl) 2013-08-27 2020-07-31 Gilead Pharmasset Llc Formulacija kombinacije dveh protivirusnih spojin
WO2015030854A1 (en) 2013-08-27 2015-03-05 Gilead Pharmasset Llc Solid dispersion formulation of an antiviral compound
TWI721947B (zh) 2014-06-11 2021-03-21 美商基利法瑪席特有限責任公司 抗病毒化合物的固態形式
TWI679203B (zh) 2014-06-11 2019-12-11 美商基利法瑪席特有限責任公司 製備抗病毒化合物之方法
JP2016051146A (ja) 2014-09-02 2016-04-11 ウシオ電機株式会社 光検出装置

Also Published As

Publication number Publication date
IL252345B (en) 2022-01-01
PL3431477T3 (pl) 2021-04-06
JP2018024705A (ja) 2018-02-15
US20150141326A1 (en) 2015-05-21
EP2907816B1 (en) 2018-06-13
AU2012318253B2 (en) 2015-08-06
NZ737924A (en) 2019-06-28
PH12015502839B1 (en) 2020-10-30
NZ752834A (en) 2021-01-29
AU2012318253B8 (en) 2015-08-13
PT3431477T (pt) 2020-12-15
EA037883B1 (ru) 2021-05-31
US9051340B2 (en) 2015-06-09
KR20180095119A (ko) 2018-08-24
US20130177530A1 (en) 2013-07-11
MX346729B (es) 2017-03-30
SI2907816T1 (sl) 2018-10-30
CN103328480B (zh) 2016-05-25
CL2013001428A1 (es) 2014-06-27
EA023644B1 (ru) 2016-06-30
KR20190121406A (ko) 2019-10-25
PE20171444A1 (es) 2017-09-29
CO6791562A2 (es) 2013-11-14
EP3431477B1 (en) 2020-10-14
CN105837584B (zh) 2018-07-13
MX2020010330A (es) 2020-10-22
CA2884712A1 (en) 2013-05-23
HRP20150725T1 (hr) 2015-08-14
KR20210043734A (ko) 2021-04-21
CA2815082C (en) 2015-07-07
EP2907816A1 (en) 2015-08-19
BR112013012091A2 (pt) 2019-09-10
MD4403B1 (ru) 2016-02-29
US8575135B2 (en) 2013-11-05
CY1121225T1 (el) 2020-05-29
MD20150091A2 (ru) 2016-02-29
EP3431477A1 (en) 2019-01-23
MD20130029A2 (en) 2013-09-30
KR20200117043A (ko) 2020-10-13
SMT201500197B (it) 2015-09-07
EP2635588A1 (en) 2013-09-11
US20180186806A1 (en) 2018-07-05
NZ610525A (en) 2017-05-26
HUE039966T2 (hu) 2019-02-28
IL252345A0 (en) 2017-07-31
US20190276468A1 (en) 2019-09-12
PL2635588T3 (pl) 2015-10-30
US8940718B2 (en) 2015-01-27
ES2544107T3 (es) 2015-08-27
RS54207B1 (en) 2015-12-31
LT2907816T (lt) 2018-09-10
US20210053981A1 (en) 2021-02-25
US20130156732A1 (en) 2013-06-20
EA030941B1 (ru) 2018-10-31
EA201390576A1 (ru) 2013-11-29
KR101890400B1 (ko) 2018-08-21
UA110354C2 (ru) 2015-12-25
EP2635588B1 (en) 2015-06-10
IL244123A0 (en) 2016-04-21
PT2907816T (pt) 2018-10-18
JP2021001230A (ja) 2021-01-07
MD4521B1 (ru) 2017-10-31
CR20130231A (es) 2013-09-19
CN103328480A (zh) 2013-09-25
CA2815082A1 (en) 2013-05-23
UA119437C2 (uk) 2019-06-25
MX2013005575A (es) 2013-09-05
US20140112885A1 (en) 2014-04-24
AU2012318253A8 (en) 2015-08-13
EP3778606A3 (en) 2021-03-03
MY173045A (en) 2019-12-20
JP2015512860A (ja) 2015-04-30
US10807990B2 (en) 2020-10-20
PE20141163A1 (es) 2014-09-21
SG10201700947UA (en) 2017-03-30
EA201890333A1 (ru) 2018-10-31
KR102036469B1 (ko) 2019-10-24
HRP20181384T1 (hr) 2018-12-28
ES2843023T3 (es) 2021-07-15
MX361735B (es) 2018-12-14
US20180244683A1 (en) 2018-08-30
ES2687291T3 (es) 2018-10-24
US20140309432A1 (en) 2014-10-16
PT2635588E (pt) 2015-09-14
US9809600B2 (en) 2017-11-07
CY1116987T1 (el) 2017-04-05
KR20140096239A (ko) 2014-08-05
DK2635588T3 (en) 2015-09-07
ECSP13012790A (es) 2013-10-31
JP2016199593A (ja) 2016-12-01
US20130164260A1 (en) 2013-06-27
AU2012318253A1 (en) 2013-05-30
EP3778606A2 (en) 2021-02-17
WO2013075029A1 (en) 2013-05-23
US9868745B2 (en) 2018-01-16
SI3431477T1 (sl) 2021-01-29
IL244122A0 (en) 2016-04-21
NZ720856A (en) 2017-12-22
MD4521C1 (ru) 2018-05-31
US9221833B2 (en) 2015-12-29
IL226345A (en) 2016-03-31
CN105837584A (zh) 2016-08-10
US20160083394A1 (en) 2016-03-24
US20200071337A1 (en) 2020-03-05
DK2907816T3 (en) 2018-09-24
IL226345A0 (en) 2013-07-31
SI2635588T1 (sl) 2015-10-30
JP6082749B2 (ja) 2017-02-15
PH12015502839A1 (en) 2019-05-15
IL244124A0 (en) 2016-04-21
HUE027733T2 (en) 2016-10-28
PL2907816T3 (pl) 2019-03-29
ME02196B (me) 2016-02-20
RS57638B1 (sr) 2018-11-30
JP2019206597A (ja) 2019-12-05
KR102241651B1 (ko) 2021-04-20
AP2013006877A0 (en) 2013-05-31
MD4403C1 (ru) 2016-09-30
HK1188989A1 (en) 2014-05-23
MA34727B1 (fr) 2013-12-03
ECSP18048718A (es) 2018-07-31
US20150299213A1 (en) 2015-10-22
US20170145027A1 (en) 2017-05-25
US8921341B2 (en) 2014-12-30
EA201591244A1 (ru) 2016-02-29

Similar Documents

Publication Publication Date Title
EA202190619A1 (ru) Противовирусные соединения
EA201590868A1 (ru) Противовирусные соединения
EA201790963A1 (ru) Противовирусные соединения
EA201790515A1 (ru) Противовирусные соединения
EA201490567A1 (ru) Новые бициклические производные дигидрохинолин-2-она
EA201491811A1 (ru) АНТИ-LgR5 АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ
EA201400976A1 (ru) Бензодиоксаны в комбинации с другими активными средствами для ингибирования продуцирования лейкотриена
EA201490596A1 (ru) Новые производные дигидрохинолин-2-она
UA113062C2 (xx) Похідні 5-фтор-4-іміно-3-(заміщеного)-3,4-дигідропіримідин-2(1h)ону
EA201391561A1 (ru) Новые соединения-модуляторы gpr-119
EA201490474A1 (ru) Аминохиназолины в качестве ингибиторов киназ
EA201691216A1 (ru) Композиции линаклотида с замедленным высвобождением
EA201391274A1 (ru) Аминохинолины в качестве ингибиторов киназ
EA201590887A1 (ru) Композиция
EA201301181A1 (ru) Триазолопиридины
EA201391489A1 (ru) Композиции со сниженной вязкостью
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
EA201490037A1 (ru) Антагонисты trpv4
EA201491149A1 (ru) Пиразолопиридиновые производные, способы их получения и их терапевтическое применение
EA201490423A1 (ru) СПОСОБЫ И КОМПОЗИЦИИ, ОТНОСЯЩИЕСЯ К p62, ДЛЯ ЛЕЧЕНИЯ И ПРОФИЛАКТИКИ РАКА
EA201400623A1 (ru) Новые 2h-индазолы в качестве антагонистов рецептора ep
EA201391265A1 (ru) Амиды индолкарбоновых и бензимидазолкарбоновых кислот в качестве инсектицидов и акарицидов
EA201590041A1 (ru) Твердая форма холиновой соли вемурафениба
EA201591717A1 (ru) Твердые формы гидрохлорида вемурафениба
EA201590116A1 (ru) Способ получения замещенных триазолопиридинов